Compass Pathways PLC Sponsored ADR (CMPS) - What Are Researchers Saying About This Stock?

Key Points

• Analyst sentiment is broadly positive: Compass Pathways has a “Moderate Buy” consensus from 17 analysts, including 14 buy ratings and one strong-buy rating. The average 12-month price target is $23.36.
• Institutional ownership remains significant: Hedge funds and other institutional investors own 46.19% of CMPS, with several firms recently increasing their positions or initiating new stakes.
• The company remains loss-making and volatile: Shares opened at $11.18, compared with a 52-week range of $4.88 to $15.87, while the latest quarterly loss of $1.88 per share significantly missed the $0.39 consensus estimate.

Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the seventeen research firms that are presently covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, fourteen have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year price objective among analysts that have issued a report on the stock in the last year is $23.36.

A number of brokerages recently weighed in on CMPS. Jefferies Financial Group reissued a "buy" rating on shares of Compass Pathways in a research report on Wednesday, September 9th. Oppenheimer reaffirmed an "outperform" rating on shares of Compass Pathways in a report on Wednesday, August 5th. BTIG Research upped their price target on shares of Compass Pathways from $14.00 to $25.00 and gave the company a "buy" rating in a research report on Tuesday, July 7th. Stifel Nicolaus increased their price target on shares of Compass Pathways from $14.00 to $21.00 and gave the stock a "buy" rating in a research note on Tuesday, July 7th. Finally, Morgan Stanley lifted their price objective on shares of Compass Pathways from $17.00 to $18.00 and gave the company an "overweight" rating in a research note on Thursday, August 6th.

Institutional Trading of Compass Pathways

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Ancora Advisors LLC acquired a new stake in Compass Pathways during the 2nd quarter worth approximately $43,000. EverSource Wealth Advisors LLC increased its holdings in shares of Compass Pathways by 67.7% in the first quarter. EverSource Wealth Advisors LLC now owns 4,754 shares of the company's stock valued at $26,000 after purchasing an additional 1,920 shares during the period. Parallel Advisors LLC increased its holdings in shares of Compass Pathways by 8,450.6% in the first quarter. Parallel Advisors LLC now owns 7,268 shares of the company's stock valued at $40,000 after purchasing an additional 7,183 shares during the period. North Star Investment Management Corp. raised its stake in shares of Compass Pathways by 1,354.0% during the first quarter. North Star Investment Management Corp. now owns 7,517 shares of the company's stock worth $42,000 after purchasing an additional 7,000 shares during the last quarter. Finally, WINTON GROUP Ltd raised its stake in shares of Compass Pathways by 20.1% during the second quarter. WINTON GROUP Ltd now owns 17,900 shares of the company's stock worth $253,000 after purchasing an additional 3,000 shares during the last quarter. 46.19% of the stock is owned by hedge funds and other institutional investors.

Compass Pathways Stock Performance

NASDAQ:CMPS opened at $11.18 on Monday. Compass Pathways has a 1 year low of $4.88 and a 1 year high of $15.87. The stock has a market cap of $1.55 billion, a P/E ratio of -2.42 and a beta of 2.55. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.30 and a current ratio of 1.30. The stock has a 50-day simple moving average of $13.10 and a 200-day simple moving average of $11.91.

Compass Pathways (NASDAQ:CMPS - Get Free Report) last issued its earnings results on Wednesday, August 5th. The company reported ($1.88) earnings per share for the quarter, missing the consensus estimate of ($0.39) by ($1.49). As a group, analysts anticipate that Compass Pathways will post -1.26 earnings per share for the current fiscal year.

Compass Pathways Company Profile

Compass Pathways plc is a biotechnology company developing novel treatments for mental health conditions. The company's lead investigational product is COMP360, a proprietary formulation of synthetic psilocybin administered with psychological support in a controlled clinical setting.

Compass Pathways has focused primarily on treatment-resistant depression, a condition in which patients do not respond adequately to existing therapies. Its research programs have included mid- and late-stage clinical trials designed to evaluate the safety and effectiveness of COMP360, as well as studies exploring its potential use in other mental health disorders.

Founded in 2016 and headquartered in London, Compass Pathways conducts research and clinical development activities across the United States, the United Kingdom and other international markets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.